Objective-During atherosclerosis, LDLs (low-density lipoproteins) accumulate in the arteries, where they become modified, aggregated, and retained. Such deposits of aggregated LDL (agLDL) can be recognized by macrophages, which attempt to digest and clear them. AgLDL catabolism promotes internalization of cholesterol and foam cell formation, which leads to the progression of atherosclerosis. Therapeutic blockade of this process may delay disease progression. When macrophages interact with agLDL in vitro, they form a novel extracellular, hydrolytic compartment-the lysosomal synapse (LS)-aided by local actin polymerization to digest agLDL. Here, we investigated the specific regulators involved in actin polymerization during the formation of the LS. Approach and Results-We demonstrate in vivo that atherosclerotic plaque macrophages contacting agLDL deposits polymerize actin and form a compartment strikingly similar to those made in vitro. Live cell imaging revealed that macrophage cortical F-actin depolymerization is required for actin polymerization to support the formation of the LS. This depolymerization is cofilin-1 dependent. Using siRNA-mediated silencing, pharmacological inhibition, genetic knockout, and stable overexpression, we elucidate key roles for Cdc42 Rho GTPase and GEF (guanine nucleotide exchange factor) Vav in promoting actin polymerization during the formation of the LS and exclude a role for Rac1. Conclusions-These results highlight critical roles for dynamic macrophage F-actin rearrangement and polymerization via cofilin-1, Vav, and Cdc42 in LS formation, catabolism of agLDL, and foam cell formation. These proteins might represent therapeutic targets to treat atherosclerotic disease. Visual Overview-An online visual overview is available for this article.
O ne of the most critical initiating factors in atherosclerosis is the deposition of LDL in the endothelial subintima of the arteries. 1 LDL contains apoB (apolipoprotein B), and during the early stages of atherosclerosis, LDL binds to the extracellular matrix of the arterial intima via electrostatic interactions between specific positively charged aminoacyl residues in apoB and negatively charged proteoglycans in the extracellular matrix. 2, 3 Matrix-associated proteoglycans biglycan, perlecan, and versicab have been shown to play an important role in apoB lipoprotein retention and atherosclerosis. [4] [5] [6] After retention, LDL within the arterial wall is known to undergo several modifications by the action of many enzymes. These include secretory sphingomyelinase, lipoprotein lipase, and the nonpancreatic secretory group V phospholipase-A 2 , which are implicated in apoB lipoprotein retention, aggregation, and atherogenesis. 4, [7] [8] [9] [10] [11] LDL also undergoes oxidative modifications within the plaque, and oxidized LDL has been linked to plaque instability and disease progression. 12, 13 Injected fluorescent LDL has been shown to aggregate and accumulate in the arterial wall, 10 and aggregates of LDL have been visualized in the subendothelial intima by electron microscopy in mice. 14, 15 LDL is known to aggregate in human atherosclerotic lesions, and this process has been proposed to be dependent on secretory sphingomyelinase. 16 Aggregation of apoB lipoprotein within the arterial wall has been implicated to accelerate lipoprotein retention and atherogenesis, as lipid hydrolysis and other modifications of the retained aggregated lipoproteins (agLDLs) release biologically active byproducts that recruit macrophages and other cells to the developing lesion. 17 This has led to the response to retention model that has become a central paradigm in the initiation and progression of atherosclerosis. 17 Further, the importance of LDL aggregation was underscored by a recent study showing that susceptibility to LDL aggregation predicted future During the cellular response to retained and aggregated LDL, monocytes/macrophages traverse the endothelium and attempt to digest and clear this LDL.
14 This leads to LDL uptake and cholesterol accumulation in macrophages, resulting in foam cell formation and enhanced secretion of factors, such as MMP-7 (matrix metalloproteinase-7), that promote inflammation. 18 Foam cells are prone to necrosis, which releases cholesterol and other metabolites into the surrounding area. This further promotes local inflammation and contributes to plaque growth. 19 Evidence suggests that the maladaptive macrophage response to agLDL exacerbates atherosclerosis and therapeutic intervention to impede macrophage catabolism of agLDL might slow the progression of atherosclerosis. 17, 18 This hypothesis was supported by a recent study showing that progranulin deficiency in the hematopoietic compartment enhances macrophage catabolism of agLDL, subsequent foam cell formation induced by agLDL (but not monomeric LDL species), and accelerated atherosclerosis in mice. 20 Therefore, a thorough understanding of the mechanisms regulating macrophage digestion of agLDL and uptake of cholesterol may lead to new therapies to slow the progression of atherosclerosis.
In contrast to monomeric LDL species, on contact with agLDL, macrophages form an extracellular compartment to which lysosomal contents are secreted, which we have called the lysosomal synapse (LS). 21 Formation of the LS occurs through local actin polymerization, 22 which allows a close apposition of plasma membrane to the agLDL, and promotes sequestration of agLDL into deeply invaginated structures, which remain topologically extracellular. 21 This sequestration allows secreted lysosomal contents to accumulate and allows the establishment of a low pH environment. 21, 23 Although actin polymerization is essential for reshaping plasma membrane and for LS formation, once the compartment is formed, it seems that actin polymerization is dispensable for maintenance of the compartment. 21 We have suggested that integrin binding may promote stable binding and allow the compartment to be stably maintained.
Actin polymerization occurs in many instances within the cell. The most well-characterized examples of actin polymerization are during phagocytosis and cell migration. The Rho GTPase family of proteins regulates actin polymerization during both processes, with Rac1 (Ras-related C3 botulinum toxin substrate 1), Rac2 (Ras-related C3 botulinum toxin substrate 2), Cdc42 (cell division control protein 42 homolog), RhoA (Ras homolog family, member A), and RhoG (Ras homolog family, member G) being the most critical proteins involved in phagocytosis [24] [25] [26] and cell migration. [27] [28] [29] Rac1, Rac2, and Cdc42 are found to be activated at the leading edge of the cell and allow protrusions called lamellipodia and filopodia to be extended from the cell to aid migration and phagocytosis. 30, 31 RhoA is known to be activated at the rear of the cell to promote cell contraction and uropod retraction. 32 During phagocytosis, Rac1, Rac2, and Cdc42 show distinct localizations of activation, perhaps reflecting similar but distinct functions in actin polymerization during phagocytosis. 33 Rac1, Rac2, and Cdc42 regulate actin polymerization during Fcγ-mediated phagocytosis, and RhoA and RhoG are critical during CR3 (complement receptor 3)-mediated phagocytosis. 25 An important factor during the process of actin polymerization is the availability of actin monomers and barbed ends, to which actin monomers can be added. Actin-severing proteins, such as cofilin, ADF (actin-depolymerizing factor), and actin-binding proteins, such as coronins, allow turnover of F-actin and promote reshaping of the cytoskeleton. 34, 35 Cofilin is known to be regulated by PI(4,5)P 2 (phosphatidylinositol 4,5-bisphosphate), and hydrolysis of PIP 2 by PLC (phospholipase C) at the plasma membrane releases cofilin, which can then bind to and sever F-actin, inducing actin polymerization and lamellipod formation. 36 Cofilin can also be inactivated by LIM kinase-dependent phosphorylation. 37 We have previously shown that actin polymerization is essential for the formation of the LS and that various types of macrophages and macrophage-like cells, including J774, RAW 264.7, bone marrow-derived macrophages (BMMs), and mouse peritoneal macrophages polymerize actin to form a similar compartment. 21, 22 We determined that RhoA plays a negative role in LS formation. 38 We have implicated Rac/Cdc42 in the process of actin polymerization during LS formation, 22 but we are yet to determine which specific proteins are involved. Further, although we have observed the LS in vitro, 21 the relevance of this type of structure in an atherosclerotic plaque is yet to be determined. Using a microscopy-based approach, here we find that in atherosclerotic plaques, macrophages make a compartment with aggregates of LDL that strikingly resembles the LS. We show that cortical F-actin rearrangement is critical for actin polymerization during LS formation, and this process is dependent on cofilin-1. Finally, we find that Vav and Cdc42, but not Rac1, regulate actin polymerization at the LS and agLDL catabolism. These data highlight critical roles for dynamic actin and Vav/Cdc42 and provide a new understanding of how macrophages can catabolize agLDL and become foam cells in the context of atherosclerosis.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. 28 Legs from euthanized mice were shipped on ice in DMEM medium supplemented with 10% FBS, 50 units per mL penicillin, and 50 μg/mL streptomycin. On arrival, bone marrow cells were isolated as described above.
Cells and Cell Culture

Reagents
Alexa Fluor 546 (Alexa546), LipidTOX Green, Alexa488-phalloidin and Alexa647-phalloidin, Alexa546-anti-rabbit, and Alexa633-antirat secondary antibodies were purchased from Invitrogen. Vectashield mounting medium with DAPI and lipofectamine RNAiMAX reagent and Opti-MEM media were purchased from Thermo Fisher Scientific (Waltham, MA). ZCL 278 and anti-tubulin antibody (clone DM1A) were purchased from Sigma-Aldrich (St. Louis, MO). pEYFP-C1 plasmid was a gift from Mark Philips (NYU School of Medicine, New York, NY). EYFP (enhanced yellow fluorescent protein)-Rac1 (Addgene plasmid No. 11391), EYFP-Rac2 (Addgene plasmid No. 11393), and EYFP-Cdc42 (Addgene plasmid No. 11392) were a gift from Joel Swanson. LifeAct-GFP (green fluorescent protein) plasmid was purchased from Ibidi USA, Inc (Fitchburg, WI). Anti-calnexin (ab22595), anti-GAPDH (ab9485), anti-ApoB (ab20737), and anti-F4/80 (ab6640) antibodies were purchased from Abcam (Cambridge, MA). Anti-cofilin-1 (No. 5175) antibody was purchased from Cell Signaling Technology (Danvers, MA). Anti-rac1 (ARC03) and anticdc42 (ACD03) antibodies were purchased from Cytoskeleton, Inc (Denver, CO). Anti-rac2 (sc-96) antibody was purchased from Santa Cruz Biotechnology, Inc (Dallas, TX). Flexitube siRNA oligos specific for murine cofilin-1, Rac1, Cdc42, and AllStars negative control siRNA were purchased from Qiagen (Germantown, MD). Fugene HD reagent was purchased from Promega (Madison, WI). Amaxa Cell Line Nucleofector Kit T was purchased from Lonza (Basel, Switzerland).
Lipoproteins
Human LDL was prepared from donor plasma as described previously. 40 LDL was labeled using succinimidyl esters of Alexa546. LDL was aggregated by vigorous vortexing for 30 seconds. 41 Alexa546-LDL was oxidized by incubation with 5 µmol/L CuSO 4 for 24 hours at 37°C, and oxidation was terminated by addition of 300 µmol/L EDTA. This was then extensively dialyzed against PBS.
Confocal Microscopy
For imaging, cells were plated on Poly-D-lysine-coated glass coverslip bottom dishes. Images were acquired with a Zeiss LSM510 or LSM880 laser scanning confocal microscope using a 40× air, 0.8 NA (numerical aperture) or 40× oil, 1.3 NA objectives, respectively. For actin measurements, z stacks were obtained with a step size of 0.98 μm. All data (besides 3-dimensional [3D] reconstruction) were analyzed with MetaMorph image analysis software (Molecular Devices, Downingtown, PA). We avoided bias in acquiring microscopy data as follows. Images were acquired from cells in the same position on each coverslip. Fields of cells were randomly acquired and only needed to fulfill the requirement of having ≥10 cells, most of which must be contacting agLDL. Alexa488 phalloidin or LipidTOX signal was only visualized after selection of a field of cells. All selected fields were imaged and included in data analysis.
Hyperlipidemic Apoe −/− Mice
Female Apoe −/− mice were obtained from Jackson Laboratories and placed on a high-fat diet (21% milk fat and 0.15% cholesterol; Harlan Teklad) for 24 weeks. Mice were euthanized, perfused with PBS, and aortas taken for sectioning.
Aortic Fixation and Sectioning
Aortas were fixed overnight in 3% (w/v) paraformaldehyde at 4°C. Fixed aortas were placed in a solution of 30% sucrose in PBS and stored at 4°C overnight. Aortas were then gently agitated in embedding media (1:2 ratio of 30% sucrose in PBS in optimal cutting temperature medium) and then frozen in the same media using 2-methylbutane and liquid nitrogen. Samples were then cut into 8-μm sections using a Cryostat, mounted onto glass slides and stored at −80°C.
Immunohistochemistry
After blocking with 5% FBS for 1 hour at room temperature, macrophages were identified using a rat monoclonal antibody for F4/80 at 1:100 dilution and LDL stained using a rabbit anti-ApoB antibody at 1:100 dilution overnight at 4°C. Samples were washed with PBS and then incubated with Alexa546 anti-rabbit and Alexa633 anti-rat secondary antibodies at 1:250 and 1:400 dilution, respectively, for 4 hours at room temperature. F-actin was stained using 0.02 U/mL Alexa488-phalloidin for 1 hour at room temperature. All antibody labeling was performed in PBS containing 2% FBS. Samples were washed with PBS and coverslips attached using Vectashield mounting medium before imaging.
3D Reconstruction of Confocal Images
Stacks of confocal images were used to make a 3D reconstruction using Imaris image analysis software (Bitplane USA, Concord, MA). Signals from DAPI (4',6-diamidino-2-phenylindole), Alexa488-phalloidin, Alexa546-ApoB, and Alexa633-F4/80 were thresholded to include only specific signal. 3D surfaces were created for each of the signals. Software was used to create movies rotating the 3D surfaces.
Foam Cell Formation
BMMs or J774 cells were treated with agLDL for 12 or 4 hours, respectively, fixed with 3% (w/v) paraformaldehyde in PBS for 20 minutes at room temperature, washed with PBS, and then stained using LipidTOX Green (at 1:1000 dilution in PBS) for 15 minutes at room temperature, followed by extensive washing in PBS, before imaging.
Actin Polymerization
Cells were left untreated or pretreated where indicated, before treatment with Alexa546-agLDL for 1 hours. Cells were fixed with 3% (w/v) paraformaldehyde in PBS for 20 minutes at room temperature and stained for F-actin using 0.02 U/mL of Alexa488-phalloidin or Alexa647-phalloidin in 0.5% (w/v) saponin in PBS for 1 hour. Cells were washed extensively with PBS and then imaged.
Ox-LDL Uptake
J774 cells were treated with media containing 50 µg/mL Alexa546-OxLDL for 15 minutes at 37°C, fixed with 3% (w/v) paraformaldehyde in PBS for 20 minutes at room temperature, washed with PBS, and analyzed by confocal microscopy.
Plasmid Propagation, Transfection, and Generation of Stable Cell Lines
Plasmids obtained from agar stab cultures were purified using plasmid DNA maxiprep kits (Qiagen) according to manufacturer's instructions. RAW 264.7 macrophages were transfected using Fugene HD reagent (Promega, Madison, WI). For transient transfection, RAW 264.7 macrophages were plated onto Poly-D-lysinecoated glass coverslip bottom dishes and cultured for 4 hours. After this time, 2 µg of plasmid and 6 µL of Fugene reagent were added to 100 µL of serum-free DMEM, gently mixed and then incubated at room temperature for 15 minutes. After this time, 1 mL of complete media was added, mixed, and added to Poly-D-lysine-coated glass coverslip bottom dishes. Cells were cultured overnight and analyzed by confocal microscopy. For stable transfection, 2 µg of plasmid and 6 µL of Fugene reagent were added to 100 µL of serum-free DMEM, gently mixed and then incubated at room temperature for 15 minutes. This was mixed and gently added to RAW 264.7 cells at 70% confluency in individual wells of a 6-well plate. After 24 hours, stably expressing cells were selected by adding complete DMEM culture media containing 0.8 mg/mL G418. Cells were maintained for 4 weeks in the same media, with 2 changes of media per week.
SiRNA-Mediated Knockdown in J774 Cells
J774 cells were transfected with lipofectamine RNAiMAX reagent. J774 cells were seeded at a density of 0.125×10 6 per well in a 6-well plate in 2.5 mL complete DMEM culture media or on Poly-D-lysinecoated glass coverslip bottom dishes. Four hours later, 5 μL of transfection reagent was mixed with 245 μL Opti-MEM media, and 6 μL of 20 μM AllStars Scr negative control siRNA or a pool of 4 different siRNA sequences for cofilin-1, Rac1, or Cdc42 (1.5 μL at 20 μM each) was mixed with 244 μL Opti-MEM media. The solutions containing transfection reagent and siRNA were gently mixed and incubated at room temperature for 20 minutes. After this time, the solution was added to J774 cells in 6-well plates to make a volume of 3 mL. This was mixed, and 200 μL of this solution was added to corresponding J774 cells on coverslip dishes. Cells were cultured overnight, and extra complete media was added. After 48 hours, coverslip dishes were used to perform microscopy assays, and cells in 6-well plate were lysed and used to assess knockdown by immunoblot analysis.
SiRNA-Mediated Knockdown in BMMs
WT (wild type) BMMs cultured from C57BL/6 mice were transfected with siRNA using the Amaxa NUCLEOFECTOR I Device using Amaxa Cell Line Nucleofector Kit T. Between 4 and 5×10 6 cells were resuspended in 100 µL of nucleofector solution. Control Scr AllStars negative siRNA or a pool of 4 different siRNA sequences targeting Cdc42 was added to a final concentration of 2 µmol/L. Cells were added to cuvettes and nucleofected using program T-20. Cells were transferred to prewarmed culture media and plated into tripartition petri dishes and cultured for 48 hours. Cell solutions were trypsinized and plated into coverslip microscopy dishes for microscopy experiments or 6-well plates overnight for assessment of knockdown efficiency by immunoblot analysis. Typically, Cdc42 protein levels 72 hours post-transfection were reduced ≥60% by Cdc42 siRNA versus Scr siRNA control.
Image Quantification
Actin polymerization was assessed as described previously. 21, 22 In brief, z stacks were acquired and regions of interest were drawn around each individual cell interacting with Alexa546-agLDL. Cells not interacting with agLDL were excluded from analysis. A binary mask was created for each slice in the z stack using Alexa546-agLDL signal intensity. This binary mask was applied to the Alexa488-phalloidin image, and the integrated Alexa488-phalloidin fluorescence colocalized with Alexa546-agLDL per z slice was obtained. These values were summed for the entire stack to obtain the total integrated Alexa488 fluoresence colocalized with Alexa546-agLDL per cell. The same method was used to quantify Alexa633-phalloidin signal colocalized with Alexa546-agLDL in EYFP plasmid expressing cells. For assessment of neutral lipid content, images were thresholded to exclude any fluorescence not associated with lipid droplets. Then the integrated LipidTOX Green fluorescence per field was quantified and divided by the number of cells in the field. Cortical F-actin in Scr and cofilin-1KD cells was quantified by acquiring z stack of images, thresholding Alexa488-phalloidin signal to include only cortical F-actin and the integrated intensity obtained. These values were summed for the entire stack to obtain the total integrated Alexa488 fluoresence and divided by the number of cells per field. For quantification of Alexa546-oxLDL uptake, single confocal images were acquired and Alexa546 signal thresholded to include only Alexa546-oxLDL signal and the integrated intensity obtained. This value was then divided by the number of cells per field to give the integrated intensity per cell.
Statistics
We performed the Lilliefors normality test and determined that our data did not pass the normality test; so nonparametric tests were used. For pairwise comparison, we have used the Mann-Whitney U test. For analysis of >2 groups, we have used the Kruskal-Wallis test. All statistical comparisons were performed using GraphPad Prism 7 software.
Results
Atherosclerotic plaque macrophages, when in contact with aggregates of LDL, polymerize actin and form a compartment like macrophages in vitro. We have shown previously that in vitro macrophages, when in contact with agLDL, form the LS by local actin polymerization. 21, 22 We have postulated that lesional macrophages might make a similar compartment to digest agLDL in atherosclerotic plaques. To test this, we obtained aortic sections from hyperlipidemic Apoe −/− mice, stained F-actin using Alexa488-phallodin, and nuclei using DAPI. LDL was identified using an ApoB antibody that has been used successfully in the past to detect LDL in murine atherosclerotic lesions, 42 and macrophages were immunostained with F4/80 antibody. We used confocal microscopy to obtain stacks of images of atherosclerotic plaque ( Figure 1A ), thereby generating a 3D reconstruction of the atherosclerotic plaque ( Figure 1B and 1C ). An enlarged view of the dashed box ( Figure 1D and 1E) shows F-actin associated with F4/80-labeled cells, and this F-actin is associated with regions of agLDL within the plaque (arrows, Figure 1E ). Other examples of such interactions can also be seen within the plaque, showing F-actin surrounding lesional agLDL (arrows, Figure 1F and 1G). These can also be seen in a movie generated from the 3D reconstruction (Movie I in the online-only Data Supplement). We have shown previously that actin polymerization at contact sites with agLDL promotes macrophage plasma membrane contact with agLDL that helps form the LS. 21 F-actin is, therefore, likely used by macrophages to allow plasma membrane to interact with lesional agLDL and promote LS formation in the plaque.
We have shown in vitro that macrophages polymerize actin at contact sites with agLDL. 21 Using the same method, we acquired stacks of images of macrophages interacting with agLDL in vitro ( Figure 1H ), performed the 3D reconstruction ( Figure 1I ), and visualized F-actin associating with agLDL from the area in the dashed box (arrows, Figure 1J and 1K). A 3D reconstruction can be seen in Movie II in the online-only Data Supplement. The F-actin structures observed in vitro also appear to surround agLDL and are strikingly similar to the structures observed in atherosclerotic plaque (arrows, Figure 1F and 1G). From these data, we conclude that macrophages, when in contact with agLDL in atherosclerotic plaques, form similar structures to those observed in vitro.
Macrophage catabolism of agLDL by the LS is regulated by cortical F-actin depolymerization through cofilin-1. We have observed previously that actin is polymerized around agLDL, within an hour of exposure, to aid formation of the LS in macrophages. 21 RhoA-a known stabilizer of cortical F-actin-suppresses formation of the compartment. 38 We hypothesized that F-actin turnover might be required to facilitate polymerization of new F-actin at the LS. To visualize F-actin in live cells during the process of LS formation, we transfected macrophages with LifeAct-GFP (a peptide that binds to F-actin fused to GFP). Although J774 or BMM may be more macrophage like, RAW 264.7 cells Figure 1 . Atherosclerotic lesion macrophages polymerize actin at contact sites with LDL (low-density lipoprotein) aggregates to form compartments similar to those observed in vitro. A-G, Aortic sections from hyperlipidemic Apoe −/− mice containing atherosclerotic plaque were immunostained for LDL using antiApoB (apolipoprotein B) antibody (red) and macrophages using anti-F4/80 antibody (gray) stained for F-actin using Alexa488-phalloidin (green) and nuclei using DAPI (blue). Stacks of images were obtained by confocal microscopy (A), and stacks were used to generate a 3-dimensional (3D) reconstruction (B and C). Dashed boxes from (B-E) have been enlarged to show greater detail. F and G, Enlarged images of other regions within the plaque. Arrows highlight regions where aggregates of LDL are interacting with F-actin. H-K, Bone marrow-derived macrophages were treated with Alexa546 aggregated LDL (agLDL) for 1 h, fixed, stained for F-actin using Alexa488-phalloidin, and analyzed by confocal microscopy. Stacks of images were obtained (H) and used to generate a 3D reconstruction (I). J and K, Enlarged regions from the dashed box in (I). Arrows highlight regions where agLDL is interacting with F-actin. F-actin compartments observed in atherosclerotic plaque and in vitro appear similar. February 2019 were the only macrophage-like cells in which we were able to achieve sufficient transfection efficiencies to allow quantitative data analysis. In live RAW macrophages treated with Alexa546-agLDL, we visualized actin polymerization by LifeAct-GFP using time-lapse microscopy (arrows, Figure 2A ). Interestingly, cortical F-actin, which appears as a peripheral ring in resting cells, seemed to get depolymerized as the LS forms (arrowheads, Figure 2A ). This suggests that cortical F-actin depolymerization occurs in parallel to actin polymerization at the LS and may be required for cells to respond to agLDL. To assess this, we quantified the amount of LifeAct-GFP colocalized with agLDL (LS), total LifeAct-GFP (total), and the amount of LifeAct-GFP not localized at the compartment (non-LS) during a time course of agLDL treatment. Total LifeAct-GFP intensity remained stable ( Figure 2B ), but as cells respond to agLDL, the amount of LifeAct-GFP colocalized with agLDL (LS) increases ( Figure 2B ). This is accompanied by a corresponding decrease Figure 2 . Cortical F-actin depolymerization occurs in parallel to actin polymerization at the compartment and regulates macrophage responsiveness to aggregated low-density lipoprotein (agLDL). A and B, RAW 264.7 macrophages were transiently transfected with LifeAct-GFP (green fluorescent protein), treated with Alexa546-agLDL and imaged live cell (A). Arrows show F-actin associated with Alexa546-agLDL, and arrowheads denote cortical F-actin adjacent to sites of contact with agLDL. B, Images from (A) were used to quantify total LifeAct-GFP (total), LifeAct-GFP colocalized with the lysosomal synapse (LS), and LifeAct-GFP not localized at the LS (non-LS) for n=12 cells. Pairwise statistical comparisons between total and non-LS and LS vs LS 0′ are shown. C-F, J774 cells were transfected with scrambled (Scr) or cofilin-1 siRNA (cofilin-1KD) using Lipofectamine RNAiMAX reagent and cultured for 48 h. C, Cells were lysed, and cofilin-1 knockdown was confirmed by immunoblot analysis. D, Scr and (E) cofilin-1KD cells were treated with Alexa546-agLDL for 1 h, fixed, stained for F-actin using Alexa488-phalloidin, and analyzed by confocal microscopy. F, Confocal images were used to quantify F-actin colocalized with agLDL per cell for at least 10 fields containing >100 cells. Median and interquartile range are shown. G-K, Scr (G and H) and (I and J) cofilin-1KD cells were treated with agLDL for 4 h before fixation, neutral lipid staining using LipidTOX Green, and analysis by confocal microscopy. K, Confocal images were used to quantify LipidTOX Green per cell for at least 10 fields containing >100 cells. Error bars SEM (B and K). *P≤0.05, **P≤0.01,****P≤0.0001, #P=0.0556.
in the amount of LifeAct-GFP not colocalized with the LS (non-LS; Figure 2B ). Non-LS LifeAct-GFP signal is mostly from cortical F-actin. This suggests that in responding cells, cortical F-actin is depolymerized to allow actin polymerization at the LS. Indeed, cells do not make F-actin structures resembling the LS without contact with agLDL ( Figure I in the online-only Data Supplement).
One of the critical regulators of cortical F-actin reorganization is cofilin-1. 43 We sought to test whether cofilin-1-dependent F-actin depolymerization is required for actin polymerization at the LS. J774 cells were transfected with Scr control siRNA or cofilin-1-specific siRNA (cofilin-1KD) and cultured for 48 hours. After 48 hours post-transfection, Cofilin-1 levels were significantly reduced in cofilin-1KD cells versus Scr cells ( Figure 2C) . The cells were then tested for their ability to polymerize actin in response to agLDL after 1 hour of Alexa546-agLDL treatment. Scr cells polymerized actin robustly at the LS (arrows, Figure 2D ), whereas cofilin-1KD cells displayed a significant reduction in actin polymerization at the LS (arrows, Figure 2E ). Single-cell quantification of F-actin colocalized with agLDL revealed a significant reduction in F-actin at the LS in cofilin-1KD cells versus Scr cells ( Figure 2F) . Notably, this effect was only observed when macrophages were stimulated by agLDL to reorganize cellular actin to form the LS. In the absence of agLDL, total cellular cortical F-actin was not significantly altered in cofilin-1KD versus Scr cells ( Figure II in the online-only Data Supplement). In addition, cofilin-1-mediated effects seemed to be relatively specific to actin polymerization at the LS because we observed no significant differences in response to monomeric oxidized LDL uptake in cofilin-1KD versus Scr cells ( Figure III in the online-only Data Supplement), which do not form LS.
Lysosomal contents are secreted by macrophages at the LS, and enzymes such as lysosomal acid lipase contribute to catabolism of agLDL. 22, 23 This catabolism leads to the generation of free cholesterol from agLDL, which macrophages internalize and esterify. 22, 38 This esterified cholesterol is stored in lipid droplets, which can be visualized by staining with dyes such as LipidTOX. We hypothesized that defective actin polymerization at the LS in cofilin-1KD cells might impair agLDL catabolism. We tested this by treating Scr and cofilin-1KD cells with agLDL for 4 hours and then staining lipid droplets using LipidTOX Green. Scr cells catabolized agLDL robustly and displayed strong LipidTOX Green staining ( Figure 2G and 2H). In comparison, cofilin-1KD cells displayed reduced staining for LipidTOX Green, suggesting an impairment in cholesterol ester accumulation in lipid droplets ( Figure 2I and 2J). LipidTOX only weakly stains agLDL, and this weak labeling can readily be removed from lipid droplet-associated LipidTOX stain by thresholding. Quantification of LipidTOX staining revealed a 50% reduction in LipidTOX staining in cofilin-1KD cells compared with Scr cells (Figure 2K ). These results further support the notion that cofilin-1-mediated actin reorganization is required for LS formation, agLDL catabolism, and cholesterol uptake from agLDL.
Vav regulates actin polymerization at the LS and subsequent agLDL catabolism. Having determined that cortical F-actin disassembly is critical for actin polymerization in response to agLDL, we sought to find regulators that promote actin polymerization at the LS. We had previously found that members of the Rho GTPase family Rac/Cdc42 and RhoA can modulate actin polymerization at the LS. 22, 38 Rho GTPases are regulated by GEFs (guanine nucleotide exchange factors) that allow exchange of GDP for GTP on Rho GTPases, thereby promoting activation of these proteins. One such GEF is Vav, 44 and it exists in 3 isoforms, Vav1, Vav2, and Vav3. We . Cdc42 (cell division control protein 42 homolog) regulates actin polymerization and compartment formation in response to aggregated low-density lipoprotein (agLDL). A-C, J774 cells were transfected with scrambled (Scr), Rac1 (Ras-related C3 botulinum toxin substrate 1), or Cdc42 siRNA using lipofectamine RNAiMAX reagent and cultured for 48 h. A, Cell lysates were taken and used to confirm Rac1, and Cdc42 protein levels were reduced by immunoblot analysis. B, J774 cells treated under the same conditions were plated onto coverslip dishes and treated with Alexa546-agLDL for 1 h, fixed, stained for F-actin using Alexa488-phalloidin, and analyzed by confocal microscopy. C, Confocal images were used to quantify F-actin colocalized with agLDL per cell for at least 10 fields containing >100 cells. Median and interquartile range are shown. D-F, WT (wild type) bone marrow-derived macrophages (BMMs) were transfected with Scr and Cdc42 siRNA and cultured for 72 h. D, Cell lysates were taken and used to confirm Cdc42 protein levels were reduced by immunoblot analysis. E, BMMs treated under the same conditions were plated onto coverslip dishes and treated with Alexa546-agLDL for 1 h, fixed, stained for F-actin using Alexa488-phalloidin and analyzed by confocal microscopy. F, Confocal images were used to quantify F-actin colocalized with agLDL per cell for at least 10 fields containing >100 cells. Median and interquartile range are shown. G and H, BMMs were treated with DMSO (dimethyl sulfoxide; control) or 50 µmol/L ZCL 278 (Cdc42 inhibitor) for 30 min before treatment with Alexa546-agLDL for 1 h in the presence of inhibitor. Cells were analyzed by confocal microscopy (G) and images used to quantify F-actin colocalized with agLDL per cell for at least 10 fields containing >100 cells. Median and interquartile range are shown. n.s. indicates nonsignificant. *P<0.05, ****P<0.0001.
by LipidTOX staining (Figure 3E and 3G) . Quantification revealed a 95% reduction in LipidTOX staining in Vav123KO macrophages treated with agLDL for 12 hours compared with Vav123(+/−) ( Figure 3H ). This suggests that Vav is a critical regulator of agLDL catabolism, cholesterol uptake, and foam cell formation.
Cdc42 is an important regulator of macrophage actin polymerization in response to agLDL but Rac1 is not. Vav is known to activate Rho GTPases Rac1 and Cdc42. 45 We have previously shown that Rac/Cdc42 promotes actin polymerization in response to agLDL. 22 We, therefore, attempted to find which specific Rho GTPase proteins are important for actin polymerization. To do this, we used a siRNA-based approach in J774 cells. Specific pools of siRNA were consistently able to reduce Rac1 and Cdc42 protein levels by >80% versus control Scr siRNA 48 hours post-transfection ( Figure 4A ). We used this approach in tandem to assess the importance of Rac1 and Cdc42 in actin polymerization on agLDL treatment. Scr cells polymerized actin robustly to agLDL, as did Rac1KD cells (arrows, Figure 4B ). Cdc42KD cells displayed markedly reduced actin polymerization at sites of contact with agLDL (arrows, Figure 4B ). Singlecell quantification of this revealed a significant reduction in actin polymerization in Cdc42KD cells but not Rac1KD cells ( Figure 4C ). This single-cell quantification also revealed that Cdc42KD cells remained responsive to agLDL but that the magnitude of their response was reduced ( Figure 4C ). To confirm these results, we also used a siRNA-based approach in BMMs. WT BMMs were transfected with Scr-or Cdc42-specific siRNA. We observed reduced Cdc42 protein levels in Cdc42KD BMMs versus Scr BMMs ( Figure 4D ), although knockdown was less efficient than that observed in J774 cells. Scr and Cdc42KD BMMs were treated with Alexa546-agLDL for 1 hour. Cdc42KD BMMs displayed less actin polymerization at sites of contact with agLDL than Scr BMMs (arrows, Figure 4E ). Quantification of actin polymerization under these conditions showed a significant reduction in Cdc42KD BMMs compared with Scr BMMs ( Figure 4F) . Notably, Cdc42KD BMMs displayed a wide distribution in the magnitude of their response, perhaps because of less efficient knockdown, but still remained responsive ( Figure 4F ). In a complimentary approach, we pretreated WT BMMs with DMSO vehicle control or Cdc42 inhibitor ZCL 278 for 30 minutes before agLDL treatment. Cdc42-inhibited cells displayed less actin polymerization in response to agLDL than control-treated cells (arrows, Figure 4G ), and quantification confirmed a significant reduction in actin polymerization in Cdc42-inhibited cells ( Figure 4H ). Single-cell analysis showed that Cdc42-inhibited cells remained responsive to agLDL, but the magnitude of their response was attenuated. Taken together, these results identify Cdc42 as a major regulator of actin polymerization at the LS.
Rac2 plays a limited role in actin polymerization and agLDL catabolism. Rac2 is an important regulator of actin polymerization and phagocytosis. 37 To test the role of Rac2 in actin polymerization in response to agLDL, we used BMMs from Rac2 −/− mice (Rac2KO BMMs). First, we confirmed Rac2 could not be detected in Rac2KO BMMs ( Figure 5A ), and then we tested the actin response to agLDL. Rac2KO BMMs displayed reduced actin polymerization compared with WT BMMs in response to agLDL (arrows, Figure 5B) , and singlecell quantification revealed a significant reduction in actin polymerization around agLDL in Rac2KO BMMs compared with WT ( Figure 5C ). Single-cell analysis also revealed that Rac2KO BMMs remained responsive to agLDL but that the magnitude of the response was reduced ( Figure 5C ). To understand whether this reduction could affect agLDL catabolism and cholesterol uptake, we treated WT and Rac2KO BMMs with agLDL for 12 hours and then stained cells for neutral lipids using LipidTOX. After 12 hours, Rac2KO BMMs displayed a 33% reduction in cholesterol uptake and reesterification from agLDL compared with WT BMMs, as measured by LipidTOX staining (Figure 5D through 5H) . From these results, we conclude that Rac2 plays a limited role in actin polymerization and agLDL catabolism in response to agLDL.
Overexpression of Cdc42, but not Rac1 or Rac2, can promote actin polymerization in response to agLDL. We have reduced macrophage protein levels of Rac1, Rac2, and Cdc42 and observed various effects on actin polymerization in response to agLDL (Figures 4 and 5) . These proteins play critical roles within the cell, and there is the possibility that reducing protein levels might affect vital functions within the cell other than actin polymerization that reduces their ability to respond to agLDL. To address this issue, we created stable RAW 264.7 cell lines overexpressing EYFPtagged Rac1, Rac2, and Cdc42, as well as EYFP only as a control. We treated overexpressing cells with agLDL and then observed their response to agLDL. EYFP-only expressing cells polymerized actin well in response to agLDL, as did EYFP-Rac1-expressing and EFYP-Rac2-expressing cells (arrows, Figure 6A ). EYFP-Cdc42-expressing cells displayed a marked increase in actin polymerization at contact sites with agLDL (arrows, Figure 6A ). Single-cell quantification of this revealed a significant increase in actin polymerization in EYFP-Cdc42-expressing cells versus EFYP-only cells and no significant difference in EYFP-Rac1-expressing or EYFPRac2-expressing cells ( Figure 6B ). These data are consistent with the knockdown experiments and further support the notion that Cdc42 plays a direct role in actin polymerization in response to agLDL in macrophages. 
Discussion
LDL deposition in the arteries is an important initiating factor during atherosclerosis. Monocyte/macrophage catabolism of this LDL leading to foam cell formation is known to exacerbate atherosclerosis and promote disease progression. We and others have suggested foam cell formation as a target for therapeutic intervention. 46 Most studies to date have focused on uptake and catabolism of monomeric LDL species, especially oxidized LDL. [47] [48] [49] [50] [51] [52] Here, we sought to characterize the process of agLDL catabolism in vitro and in vivo and identify regulators of this process. It should be noted that aggregates of LDL in the vessel wall would likely become oxidized because of the oxidative environment of the plaque. 17, 53 We find that in vivo, macrophages polymerize actin to form compartments at contact sites with aggregates of LDL, like those created in vitro. We show that cortical F-actin depolymerization occurs to promote actin polymerization at the LS in a cofilin-1-dependent manner. This cofilin-1-dependent depolymerization regulates macrophage actin polymerization in response to agLDL. Finally, we show that Vav and Cdc42 play critical roles in promoting actin polymerization to form the LS. These data identify several key regulators of agLDL catabolism and foam cell formation and provide mechanistic insights into how the LS is formed by macrophages.
We have shown that F-actin depolymerization that occurs partially through cofilin-1 is necessary to regulate macrophage response to agLDL (Figure 3 ). This result likely means that cofilin-1 depolymerization of cortical F-actin is required to recycle actin monomers to aid actin polymerization and formation of the LS. We also show that actin polymerization from these monomers at the LS requires Cdc42 ( Figure 5 ). Interestingly, studies have found that there is interplay between cofilin and Cdc42. Cofilin is thought to be a downstream effector of Cdc42 because Cdc42 is known to impact the phosphorylation (and, therefore, activation status) of cofilin-1. [54] [55] [56] Curiously, both Rho and Cdc42, but not Rac, were found to have the ability to modulate cofilin activity. 54 We have previously shown that RhoA can regulate actin polymerization 38 and show here that Cdc42 but not Rac can promote actin polymerization at the LS in response to agLDL. Therefore, cofilin-1 may be a shared effector by which Rho and Cdc42 can modulate actin responses to agLDL at the LS.
One question raised by this study is what the exact role of Rac2 is. Knockout of Rac2 inhibits actin polymerization and foam cell formation in response to agLDL ( Figure 5 ). However, overexpression of Rac2 did not increase actin polymerization to agLDL ( Figure 6 ). From these data, it seems likely that Rac2 expression is not a limiting factor in actin polymerization at the LS. A possible explanation for this inconsistency is that Rac2 deficiency in Rac2KO macrophages causes long-term effects that inhibit their ability to respond to agLDL. Another reason could be that overexpression of WT Rac2 does not increase levels of activated Rac2 because of limits in GEF activity. Another explanation could be that Rac2 plays other roles within the cell and that overexpression of Rac2 has other effects within the cell. These questions will be answered through further study.
Further investigation is required to elucidate the role of other effectors downstream of Rho and Cdc42. The aim of such studies would be to find effector proteins with limited expression or a cell type-specific role that could be exploited therapeutically, with greater specificity than targeting RhoA or Cdc42, which are ubiquitously expressed. It would be important to determine the role of such proteins in the plaque microenvironment. We have previously suggested that cholesterol and plaque metabolites, such as ceramide, can activate RhoA, 38 which might contribute to macrophage retention in plaques. This is particularly significant because recent data have suggested that the predominant source of macrophages within plaques is through local proliferation of trapped macrophages. 57 Therefore, therapeutic intervention of this signaling pathway might serve the dual purpose of halting macrophage catabolism of plaque LDL (and, therefore, inhibiting foam cell formation) and promoting macrophage egress from the plaque. Further studies will test the feasibility of such an approach.
